We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
Cap. Flow
+$783M
Cap. Flow %
17.35%
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$94.6M
2
AZN icon
AstraZeneca
AZN
+$82.2M
3
BAX icon
Baxter International
BAX
+$68.1M
4
CRBU icon
Caribou Biosciences
CRBU
+$60.5M
5
STVN icon
Stevanato
STVN
+$59.9M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$124M
2
MDT icon
Medtronic
MDT
+$66.4M
3
BIIB icon
Biogen
BIIB
+$63.7M
4
NEO icon
NeoGenomics
NEO
+$61.7M
5
LLY icon
Eli Lilly
LLY
+$58.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.59%
2 Technology 0.99%
3 Financials 0.53%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
51
Altimmune
ALT
$556M
$24.5M 0.54%
+2,167,900
New +$26.4M
VIR icon
52
Vir Biotechnology
VIR
$1.46B
$22.4M 0.5%
515,000
+353,000
+218% +$15.3M
ALPN
53
DELISTED
Alpine Immune Sciences Inc
ALPN
$20.6M 0.46%
1,932,000
+437,000
+29% +$4.03M
EPIX
54
DELISTED
ESSA Pharma
EPIX
$19.6M 0.43%
2,450,000
-300,000
-11% -$4.77M
ACET icon
55
Adicet Bio
ACET
$75.7M
$19M 0.42%
151,225
+10,569
+8% +$1.31M
IPSC icon
56
Century Therapeutics
IPSC
$359M
$18.6M 0.41%
739,269
-264,253
-26% -$7.15M
SIBN icon
57
SI-BONE Inc
SIBN
$787M
$17.8M 0.39%
831,200
+256,200
+45% +$6.48M
SANA icon
58
Sana Biotechnology
SANA
$899M
$17.4M 0.39%
774,644
-3,953
-0.5% -$83K
PATH icon
59
UiPath
PATH
$6.19B
$16.8M 0.37%
319,000
+19,000
+6% +$1.15M
REUN
60
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$16.4M 0.36%
+716,200
New +$18M
LFST icon
61
Lifestance Health
LFST
$4.17B
$14.5M 0.32%
1,000,000
-100,000
-9% -$1.93M
PHAS
62
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$13.7M 0.3%
4,405,000
+90,000
+2% +$300K
WGS icon
63
GeneDx Holdings
WGS
$1.9B
$12.6M 0.28%
50,303
+34,394
+216% +$11.8M
GHRS icon
64
GH Research
GHRS
$1.88B
$12.4M 0.27%
560,000
– –
LENZ
65
LENZ Therapeutics
LENZ
$180M
$12.3M 0.27%
106,999
+1,928
+2% +$286K
ACIU icon
66
AC Immune
ACIU
$234M
$11.7M 0.26%
1,739,600
+155,600
+10% +$1.11M
SCYX icon
67
SCYNEXIS
SCYX
$35.9M
$10.9M 0.24%
257,500
– –
HOWL icon
68
Werewolf Therapeutics
HOWL
$21.8M
$10.7M 0.24%
625,120
-25,145
-4% -$429K
S icon
69
SentinelOne
S
$6.27B
$10.7M 0.24%
200,000
– –
HARP
70
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.41M 0.21%
119,060
-30,940
-21% -$3.11M
ESMT
71
DELISTED
EngageSmart, Inc.
ESMT
$9.37M 0.21%
+275,000
New +$9.45M
ACAD icon
72
Acadia Pharmaceuticals
ACAD
$4.38B
$9.14M 0.2%
550,000
-390,000
-41% -$7.52M
ORTX
73
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$8.82M 0.2%
383,680
+5,500
+1% +$164K
CMAX
74
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$7.99M 0.18%
27,580
+333
+1% +$98K
ZETA icon
75
Zeta Global
ZETA
$5.41B
$7.62M 0.17%
1,300,000
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2021 Portfolio in Review

As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $783M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 95% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.

  • Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
  • Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
  • Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
  • Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
  • Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
  • Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.